Moncef Slaoui, PhD, the chief advisor of Operation Warp speed, the White House task force to develop a COVID-19 vaccine, said drugmakers establishing COVID-19 vaccines will start to seek FDA emergency approval around Thanksgiving, according to an Oct. 10 MarketWatch interview with the immunologist.
” We will know if a vaccine works … anytime late October, or November, or in December,” Dr. Slaoui informed MarketWatch. Possibly if we work like crazy we make it take place in two weeks.”.
© Copyright ASC COMMUNICATIONS 2020.
More short articles on drug store: COVID-19 vaccine trial recruiters discuss extensive mistrust, false information amongst prospective enrollees7 key uncertainties surrounding the COVID-19 vaccine raceRemdesivir cuts COVID-19 healing time by 5 days, last research study information states.
Dr. Slaouis estimated timeline comes days after the White House endorsed the FDAs new COVID-19 vaccine permission standards, which require a two-month observation duration after medical trial participants are provided the last dosage of the vaccine to see if there are any unfavorable negative effects. He called the requirement “reasonable” and “a great takeaway.”.
Katie Adams –
Monday, October 12th, 2020
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
” We will understand if a vaccine works … anytime late October, or November, or in December,” Dr. Slaoui informed MarketWatch. Maybe if we work like insane we make it occur in two weeks.”.
FDA standards also need that vaccines be at least 50 percent reliable in preventing COVID-19. Dr. Slaoui informed MarketWatch he expects the vaccines looking for emergency situation approval in the coming months to be between 80 and 90 percent efficient, stating he would be “extremely adversely surprised if it was closer to 50 percent.”.